LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $8.60 Consensus Target Price from Analysts

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have received a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.83.

A number of brokerages have issued reports on LFST. Barclays upped their price target on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Thursday, February 29th. Morgan Stanley restated an “overweight” rating and set a $10.00 price target on shares of LifeStance Health Group in a research note on Monday. The Goldman Sachs Group upped their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday, March 4th. Finally, Jefferies Financial Group increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th.

Insider Transactions at LifeStance Health Group

In related news, insider Kevin Michael Mullins sold 115,136 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $8.02, for a total transaction of $923,390.72. Following the sale, the insider now owns 4,575,480 shares in the company, valued at $36,695,349.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Kevin Michael Mullins sold 115,136 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the transaction, the insider now directly owns 4,575,480 shares of the company’s stock, valued at $36,695,349.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO David Bourdon sold 58,826 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $6.93, for a total transaction of $407,664.18. Following the completion of the transaction, the chief financial officer now directly owns 433,856 shares in the company, valued at $3,006,622.08. The disclosure for this sale can be found here. Insiders have sold 245,463 shares of company stock worth $1,786,868 over the last 90 days. 8.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC lifted its stake in LifeStance Health Group by 35.4% in the third quarter. Jennison Associates LLC now owns 2,046,358 shares of the company’s stock worth $14,058,000 after acquiring an additional 535,358 shares during the last quarter. FMR LLC increased its holdings in shares of LifeStance Health Group by 6.7% in the 3rd quarter. FMR LLC now owns 28,178,666 shares of the company’s stock valued at $193,587,000 after purchasing an additional 1,758,427 shares in the last quarter. SG Americas Securities LLC purchased a new position in LifeStance Health Group during the 3rd quarter valued at about $206,000. Principal Financial Group Inc. increased its holdings in LifeStance Health Group by 4.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,895,887 shares of the company’s stock valued at $26,765,000 after acquiring an additional 168,091 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in LifeStance Health Group during the 3rd quarter valued at about $34,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Trading Up 1.0 %

NASDAQ:LFST opened at $6.17 on Monday. LifeStance Health Group has a 52 week low of $4.74 and a 52 week high of $9.59. The firm has a 50 day moving average of $6.46 and a 200 day moving average of $6.53. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -12.10 and a beta of 1.34.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. The firm had revenue of $280.60 million for the quarter, compared to analysts’ expectations of $263.14 million. As a group, sell-side analysts anticipate that LifeStance Health Group will post -0.3 earnings per share for the current fiscal year.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.